This approach involves customization of specific lipid components for mRNA delivery, independent of cGAS activation of STING.195 Furthermore, the use of mRNA encoding cGAS or STING has been found to activate antigen-presenting cells involved in tumor infiltration, enhancing IFN signaling pathways to enhance CD8+ T cell responses.196 Despite the highest adjuvant activity observed in patients with the STINGV155M mutation associated with early-onset STING-associated vasculopathy of infancy (SAVI), potential T cell cytotoxic side effects should be considered.196. The gene discussed is STING1; the disease is neoplasm.